The beneficial effects of the angiotensin converting enzyme (ACE) inhibitors in heart failure appear to be independent-at least in part-of their effects on blood pressure.' It has therefore been proposed that a local reninangiotensin system exists in the heart, but this is still a controversial issue. In our opinion it is justified to use the term "local renin-angiotensin system" when angiotensin II is locally produced by renin synthesised in situ. Only when these conditions are met can such a system be said to operate independently of the kidney. There is, however, a growing body of evidence favouring uptake of renin from the circulation by the heart. The question of local renin formation versus uptake will be addressed in this paper. Cardiovasculair Onderzoeksinstituut Erasmus Universiteit Rotterdam (COEUR),
Renin-angiotensin system components in cardiac tissue Measurements of gene expression, at both protein and mRNA level, have been used to show the existence of a cardiac renin-angiotensin system. Protein measurements cannot be taken as evidence that the protein is synthesised locally. Moreover, such measurements are often hampered by a lack of specificity. For example, the presence of renin activity in tissue extracts may be caused by enzymes other than renin that are capable of generating angiotensin I. Detection of mRNA, particularly when the concentrations are low, does not necessarily mean that the corresponding protein is synthesised locally in physiologically relevant amounts. 2 We compared the renin level in the heart with its level in blood plasma in normal and nephrectomised pigs.3 Angiotensin I generating activity of cardiac tissue was identified as renin by its inhibition by a specific active site directed renin inhibitor. The levels of renin in cardiac tissue (expressed per g wet weight) were found to be similar to those in plasma (table 1). The tissue levels of renin, therefore, cannot be accounted for by trapped plasma. Both in cardiac tissue and in plasma, renin fell to unde- tectable levels after nephrectomy (fig 1) , suggesting that most, if not all, renin present in the heart originates from the kidney. Indeed, studies in which bolus injections of radiolabelled renin were given to monkeys or rats showed accumulation of radioactivity not only in liver and kidney but also-albeit in lower amounts-in the heart.45 Since renin, like ACE, was enriched in a purified cardiac membrane fraction prepared from left ventricular tissue, uptake of kidney derived renin by the heart may occur through binding to cell membranes.' Binding to cell membranes is also suggested by chemical crosslinking studies using membrane fractions prepared from various tissues, including heart and blood vessels.6 In early studies in sheep,'9 angiotensin II clearance across the pulmonary and combined systemic vascular beds was calculated from the arteriovenous differences measured across these beds during infusion of high doses of angiotensin II into the pulmonary artery. These studies already indicated that angiotensin II is rapidly degraded and that plasma renin activity is probably insufficient to generate the levels of endogenous angiotensin II measured in circulating blood.
More recently, the regional clearance and metabolism of angiotensin I and angiotensin II have been quantified, both in humans2-22 and in pigS,23 24 to originate from angiotensin II delivered by the artery and from that generated by conversion of arterially delivered angiotensin I. Thus angiotensin I produced at tissue sites and released into the circulation may have escaped conversion to angiotensin II. It is possible that angiotensin I produced in the tissue enters the blood at a level distal to the site where arterially delivered angiotensin I is converted to angiotensin II by the vascular endothelium, so that this conversion site is bypassed. Angiotensin I formed at tissue sites may enter the circulation at the level of the capillaries or venules, whereas conversion of angiotensin I to angiotensin II occurs at the level of the arterioles. Alternatively, angiotensin II is produced in the tissue and may remain there.
The studies described above are limited to measurements of angiotensins in the circulation. We have now extended these studies by measuring the cardiac tissue levels of endogenous and radiolabelled angiotensin I and angiotensin II in pigs during 'l25-angiotensin I infusion into the left cardiac ventricle.25 Such measurements can be used to estimate the contribution of angiotensins from the circulation to the angiotensin levels in cardiac tissue. Our preliminary results indicate that the cardiac 1251-angiotensin I concentrations are less than 5% of the levels in plasma, whereas the concentrations of cardiac 125I-angiotensin II are 85-90% of plasma 1251I-angiotensin II. In these experiments the cardiac tissue concentration of angiotensin I was similar to the plasma concentration, while the cardiac tissue level of angiotensin II was four to five times higher than plasma angiotensin II. It was calculated that more than 70% of the angiotensin II present in cardiac tissue is not derived from angiotensin I in the circulation, and that more than 90% of cardiac angiotensin I is produced in the tissue itself.
As mentioned above, our measurements of circulating angiotensins during 125I-angiotensin I infusion into the left cardiac ventricle provided evidence for release of angiotensin I from cardiac tissue sites. These measurements of circulating angiotensins provided no evidence for the release of tissue angiotensin II into the circulation. Thus our data cumulatively indicate that both angiotensin I and angiotensin II are generated by cardiac tissue, and that of these locally generated angiotensins, only angiotensin I is released into the circulation. Possibly, angiotensin I and angiotensin II are formed in different tissue compartments which are not all capable of exchanging freely with the circulation.
Function of cardiac angiotensin II In view of the beneficial effects of ACE inhibitors in heart failure, where regression of cardiac hypertrophy and inhibition of postinfarction remodelling were observed, it has been postulated that angiotensin II acts as a growth factor in the heart.2627 Indeed, in isolated cardiac cells, angiotensin II induces hyperplasia (fibroblasts)28 or hypertrophy (myocytes).29 Angiotensin II also stimulates collagen production by cardiac fibroblasts.30 These effects are most probably mediated by the AT1 receptor. Recent reports suggest that the AT2 receptor, which appears to be present in the fetal but not in the adult heart,3' is involved in antiproliferation.i2
Apart from being a growth/antigrowth factor, cardiac angiotensin II may also regulate coronary flow and cardiac contractility. The effect on cardiac contractility is either a direct, AT, receptor dependent, action on cardiac myocytes, or an indirect effect through presynaptic stimulation of adrenergic nerve endings. Studies on the effects of angiotensin II on cardiac inotropy are conflicting.3334 Part of the conflicting results may be explained by species differences.34 In addition, most studies on the cardiac haemodynamic effects of angiotensin II have employed the use of ACE inhibitors. ACE acts on substrates other than angiotensin I (for example, bradykinin and substance P). Consequently, the effects of ACE inhibition on cardiac contractility may not necessarily be due only to the inhibition of angiotensin II formation.
Angiotensinogen is the only known substrate of renin. We therefore used a renin inhibitor to investigate the cardiac haemodynamic effects of angiotensin 11.35 During intracoronary infusion of the specific renin inhibitor-remikiren in pigs, a dose dependent depressant effect on cardiac contractility was observed. This effect was significantly diminished after pretreatment with a selective AT, receptor antagonist. The doses of remikiren required to cause cardiodepression were at least one order of magnitude higher than those required to suppress plasma angiotensin II. These data support the contention that myocardial contractility is increased by renin dependent angiotensin II formation in the heart.
Possible implications
The existence of a so called local renin-angiotensin system in the heart is still a matter of debate. All renin-angiotensin system components are present in cardiac tissue, and both angiotensin I and angiotensin II are produced in the heart. However, the renin responsible for this local angiotensin production, at least under normal circumstances, appears to originate from the circulation and is therefore kidney derived. Thus a local renin-angiotensin system, in the sense that the renin-angiotensin system components necessary for angiotensin II production are synthesized in situ, does not appear to exist in the normal heart.
In spite of the fact that the cardiac reninangiotensin system appears to depend on renin from the kidney, there are still many ways by which the heart may regulate its own angiotensin II production. Membrane binding could be a mechanism by which kidney derived renin is sequestered in the heart.3 Renin binding sites have been reported, and a renin binding protein has been identified in various tissues, including the heart.36 37 The density of such binding sites and the concen- tration of renin binding protein may vary, and this could modify the tissue production of angiotensin I and angiotensin II. Local concentrations of ACE may also vary. The ACE levels in the human heart are, in part, determined by the so called insertion/deletion ACE gene polymorphism (fig 2) .38 39 Also, enzymatic degradation of angiotensin II and AT, receptor mediated endocytosis could influence the angiotensin II concentrations at the cellular and subcellular level. Finally, under certain pathological conditions, renin may be produced in the heart itself,10 and this would create the possibility for the heart to regulate its own angiotensin II production, independent of the kidney.
More detailed knowledge of the actual sites of angiotensin II production in the heart and on its regulation will further illuminate the role of the renin-angiotensin system in cardiac function, growth, and remodelling, and its contribution to the cardiac effects of ACE inhibitors, AT, receptor antagonists, and renin inhibitors.
Summary
The beneficial effects of angiotensin converting enzyme (ACE) inhibitors in heart failure appear to be independent, at least in part, of their effect on blood pressure. The existence of a local cardiac renin angiotensin system is often suggested as an explanation. It has been known for some time that a substantial proportion of arterially delivered angiotensin I is converted to angiotensin II by ACE of the coronary vascular endothelium. The levels of angiotensin II in cardiac tissue are several times the levels of angiotensin II in circulating blood. Recent evidence suggests that most of the angiotensin II in the heart is not derived from angiotensin I in the circulation, and that most of the angiotensin I in cardiac tissue is generated in the tissue itself. On the other hand, renin mRNA levels are very low or undetectable in the normal heart. In addition, studies on the effects of bilateral nephrectomy on the cardiac tissue levels of renin, angiotensin I, and angiotensin II in pigs have indicated that cardiac renin originates from the kidney and that cardiac generation of angiotensin I and angiotensin II depends on renin from the kidney. Intracardiac synthesis of renin may occur under pathological conditions and during fetal development. The fact that angiotensins are generated by the heart raises the possibility of local mechanisms to regulate the concentrations of these peptides at certain tissue sites. For example, preliminary evidence suggests that binding of renin to cardiac membranes is a mechanism by which renin is taken up by the heart. A specific renin binding protein has been identified in cardiac tissue. Cardiac ACE levels may also influence local angiotensin II formation and are, in part, determined by the so called insertion/deletion ACE gene polymorphism. More detailed knowledge on the site of angiotensin generation and on its regulation will improve our understanding of the role of the renin-angiotensin system in cardiac function, hypertrophy, and postinfarction remodelling.
